During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

Multiple Myeloma is a type of blood cancer that develops in plasma ... weakening the immune system and causing complications ...

[7] Renal function was assessed in every clinic visit, on days 1, 4, 8, and 11 of a 21-day cycle, or more frequently if indicated. Response of myeloma to treatment was defined as ≥ 50% decrease ...

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Multiple myeloma is a type of cancer where plasma cells ... The accumulation of M protein in the blood can result in kidney damage and kidney failure. Hypercalcemia can also impair kidney function.

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

4, 2024 — A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma.

Multiple myeloma is a complex disease ... increased risk of infections as the immune system weakens, kidney issues and ...

Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple myeloma, after reporting that it met its objectives in a phase 3 trial.

Purpose: Renal impairment is a frequent complication of multiple myeloma (MM) and is associated with significant morbidity and increased early death rate. Bortezomib is active and well tolerated ...